Patents by Inventor Paul Michael Scola

Paul Michael Scola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunomodulators
    Publication number: 20160222060
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: February 1, 2016
    Publication date: August 4, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Immunomodulators
    Publication number: 20160176928
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Li-Qiang Sun, Qian Zhao, Eric P. Gillis, Michael Matthew Miller, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • Immunomodulators
    Publication number: 20160175386
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 23, 2016
    Inventors: Claudio Mapelli, Eric P. Gillis, Li-Qiang Sun, Qian Zhao, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20160158349
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 28, 2016
    Publication date: June 9, 2016
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Immunomodulators
    Publication number: 20160137696
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 19, 2016
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 9334279
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 10, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Eric P. Gillis, Michael S. Bowsher, Paul Michael Scola
  • Immunomodulators
    Publication number: 20160102122
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 5, 2015
    Publication date: April 14, 2016
    Inventors: Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 9308236
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Hepatitis C Virus Inhibitors
    Publication number: 20160067302
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: November 9, 2015
    Publication date: March 10, 2016
    Inventors: Alan Xiangdong Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen
  • COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20160024111
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: March 5, 2014
    Publication date: January 28, 2016
    Inventors: Tao WANG, Zhiwei YIN, Paul Michael SCOLA
  • Hepatitis C virus inhibitors
    Patent number: 9227940
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: January 5, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20150376233
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: March 3, 2014
    Publication date: December 31, 2015
    Inventors: Pulicharla Nagalakshmi, Kandhasamy Sarkunam, Kishore V. Renduchintala, Paul Michael Scola
  • MACROCYCLIC COMPOUNDS AS HCV ENTRY INHIBITORS
    Publication number: 20150368267
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Inventors: Tao WANG, Zhongxing ZHANG, Zhiwei YIN, Li-Qiang SUN, Eric MULL, Qian ZHAO, Paul Michael SCOLA
  • MACROCYCLIC MOLECULES AS HCV ENTRY INHIBITORS
    Publication number: 20150368251
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Inventors: Tao WANG, Zhongxing ZHANG, Eric GILLIS, Paul Michael SCOLA
  • Hepatitis C Virus Inhibitors
    Publication number: 20150329547
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: October 31, 2013
    Publication date: November 19, 2015
    Inventors: Eric P. Gillis, Michael S. Bowsher, Paul Michael Scola
  • AMMONIUM DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20150322085
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: January 23, 2014
    Publication date: November 12, 2015
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Paul Michael Scola
  • SQUARIC DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20150322020
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: January 23, 2014
    Publication date: November 12, 2015
    Inventors: Tao Wang, Zhongxing Zhang, Paul Michael Scola
  • GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20150320757
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: January 23, 2014
    Publication date: November 12, 2015
    Inventors: TAO WANG, Zhongxing Zhang, Ying Han, Zhiwei Yin, Paul Michael Scola
  • Compounds Useful as Immunomodulators
    Publication number: 20150291549
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: April 8, 2015
    Publication date: October 15, 2015
    Inventors: Louis S. Chupak, Min Ding, Scott W. Martin, Xiaofan Zheng, Piyasena Hewawasam, Timothy P. Connolly, Ningning Xu, Kap-Sun Yeung, Juliang Zhu, David R. Langley, Daniel J. Tenney, Paul Michael Scola
  • Hepatitis C Virus Inhibitors
    Publication number: 20150284409
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 8, 2015
    Inventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola